Jubilant Pharmova Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Jubilant Pharmova wird ein jährliches Gewinn- und Umsatzwachstum von 5.5% bzw. 10.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.7% betragen.

Wichtige Informationen

5.5%

Wachstumsrate der Gewinne

10.2%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.7%
Wachstumsrate der Einnahmen	10.3%
Zukünftige Eigenkapitalrendite	9.7%
Analystenabdeckung	Low
Zuletzt aktualisiert	26 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Nov 15

A Look At The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Oct 27

Jubilant Pharmova Limited (NSE:JUBLPHARMA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Aug 24

Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Jul 13

Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Mar 14

Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth

Dec 23

These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

Dec 02

These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

Jul 26

Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year

Sep 15

Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly

Aug 21

Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook

Jun 08

An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued

May 25

Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts

Feb 10

Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)

Feb 08

Gewinn- und Umsatzwachstumsprognosen

NSEI:JUBLPHARMA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	89,202	7,793	8,104	11,957	2
3/31/2026	80,339	5,898	6,319	10,368	2
3/31/2025	72,326	7,771	5,258	14,159	1
9/30/2024	69,197	5,931	-2,744	7,676	N/A
6/30/2024	68,477	5,528	N/A	N/A	N/A
3/31/2024	67,029	771	736	9,713	N/A
12/31/2023	66,223	378	N/A	N/A	N/A
9/30/2023	64,977	-446	133	9,836	N/A
6/30/2023	64,169	-1,017	N/A	N/A	N/A
3/31/2023	62,817	-610	-1,538	6,607	N/A
12/31/2022	61,313	964	N/A	N/A	N/A
9/30/2022	58,893	1,631	-1,596	4,924	N/A
6/30/2022	59,472	3,004	N/A	N/A	N/A
3/31/2022	61,302	4,139	2,376	8,375	N/A
12/31/2021	61,824	5,273	N/A	N/A	N/A
9/30/2021	66,432	6,953	10,175	16,021	N/A
6/30/2021	65,771	6,993	N/A	N/A	N/A
3/31/2021	60,985	5,741	12,568	17,843	N/A
12/31/2020	92,659	8,339	N/A	N/A	N/A
9/30/2020	89,744	7,759	10,031	15,596	N/A
6/30/2020	88,655	8,013	N/A	N/A	N/A
3/31/2020	59,758	6,778	9,688	15,429	N/A
12/31/2019	91,486	5,385	N/A	N/A	N/A
9/30/2019	92,105	5,959	7,357	13,374	N/A
6/30/2019	92,140	5,569	N/A	N/A	N/A
3/31/2019	91,108	5,745	4,656	11,215	N/A
12/31/2018	89,772	8,286	N/A	N/A	N/A
9/30/2018	86,679	7,803	N/A	N/A	N/A
6/30/2018	80,402	6,982	N/A	N/A	N/A
3/31/2018	75,178	6,428	N/A	13,032	N/A
12/31/2017	68,641	6,381	N/A	N/A	N/A
9/30/2017	62,545	5,449	N/A	N/A	N/A
6/30/2017	59,982	5,613	N/A	N/A	N/A
3/31/2017	58,614	5,757	N/A	12,685	N/A
12/31/2016	58,013	4,763	N/A	N/A	N/A
9/30/2016	57,097	4,795	N/A	N/A	N/A
6/30/2016	57,762	4,612	N/A	N/A	N/A
3/31/2016	57,491	3,918	N/A	10,989	N/A
12/31/2015	58,376	4,035	N/A	N/A	N/A
9/30/2015	59,036	2,754	N/A	N/A	N/A
6/30/2015	58,117	655	N/A	N/A	N/A
3/31/2015	58,262	-578	N/A	7,833	N/A
12/31/2014	58,863	-17	N/A	N/A	N/A
9/30/2014	58,837	1,529	N/A	N/A	N/A
6/30/2014	58,641	1,664	N/A	N/A	N/A
3/31/2014	58,034	1,090	N/A	7,723	N/A
12/31/2013	55,983	-207	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: JUBLPHARMADas prognostizierte Gewinnwachstum (5.5% pro Jahr) liegt unter der Sparquote (6.7%).

Ertrag vs. Markt: JUBLPHARMADie Erträge des Unternehmens (5.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (18% pro Jahr).

Hohe Wachstumserträge: JUBLPHARMADie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: JUBLPHARMADie Einnahmen des Unternehmens (10.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (10.5% pro Jahr).

Hohe Wachstumseinnahmen: JUBLPHARMADie Einnahmen des Unternehmens (10.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: JUBLPHARMADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.7%).

Jubilant Pharmova Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 34% to ₹1,170

Price target decreased by 8.9% to ₹395

Price target decreased by 11% to ₹384

Price target decreased to ₹391

Price target decreased to ₹434

Price target decreased to ₹507

Recent updates

Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Now 21% overvalued after recent price rise

A Look At The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Second quarter 2025 earnings released: EPS: ₹6.47 (vs ₹3.94 in 2Q 2024)

Now 21% overvalued after recent price rise

Price target increased by 34% to ₹1,170

Jubilant Pharmova Limited Appoints Tushar Gupta as Chief of Operations

Investor sentiment improves as stock rises 25%

Jubilant Pharmova Limited Declares Dividend for the Financial Year Ended March 31, 2024

Jubilant Pharmova Limited (NSE:JUBLPHARMA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Jubilant Pharmova Limited, Annual General Meeting, Aug 30, 2024

Jubilant Pharmova Limited, Annual General Meeting, Aug 30, 2024

Jubilant Pharmova Limited Announces the Resignation of Dr. Saji Thomas as Head-R&D (Api)

Investor sentiment improves as stock rises 18%

First quarter 2025 earnings released: EPS: ₹30.44 (vs ₹0.40 in 1Q 2024)

Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Jubilant Pharmova Limited to Report Q1, 2025 Results on Jul 19, 2024

Jubilant Pharmova Limited Announces Resignation of Jinang Pratap Parekh as Whole-Time Director, Effective May 31, 2024

Full year 2024 earnings released: EPS: ₹4.84 (vs ₹3.83 loss in FY 2023)

Jubilant Pharmova Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Third quarter 2024 earnings released: EPS: ₹4.22 (vs ₹0.98 loss in 3Q 2023)

Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth

These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023

Second quarter 2024 earnings released: EPS: ₹3.94 (vs ₹0.34 in 2Q 2023)

Price target decreased by 8.9% to ₹395

Jubilant Pharmova Limited to Report Fiscal Year 2024 Results on May 17, 2024

Jubilant Pharmova Limited, Annual General Meeting, Aug 31, 2023

These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

First quarter 2024 earnings released: EPS: ₹0.40 (vs ₹2.96 in 1Q 2023)

Jubilant Pharmova Limited to Report Fiscal Year 2023 Results on Jul 19, 2023

Jubilant Pharmova Limited Announces Change in Directorate

Full year 2023 earnings released: ₹3.83 loss per share (vs ₹26.01 profit in FY 2022)

Jubilant Pharmova Limited to Report Q4, 2023 Results on May 29, 2023

Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Price target decreased by 11% to ₹384

Third quarter 2023 earnings released: ₹0.98 loss per share (vs ₹3.20 profit in 3Q 2022)

Jubilant Pharmova Limited to Report Q3, 2023 Results on Feb 03, 2023

Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?

Price target decreased to ₹391

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jubilant Pharmova Limited to Report Q2, 2023 Results on Oct 21, 2022

Jubilant Pharmova Limited Appoints Jaidev Rajpal as Head of Its Generics Business, Effective October 11, 2022

Price target decreased to ₹434

Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before October 24, 2022

Jubilant Pharmova Limited, Annual General Meeting, Sep 26, 2022

Upcoming dividend of ₹5.00 per share

First quarter 2023 earnings released: EPS: ₹2.96 (vs ₹10.09 in 1Q 2022)

Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00

Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022

Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022

Jubilant Pharmova Limited to Report Q1, 2023 Results on Aug 02, 2022

High number of new directors

Price target decreased to ₹507

Jubilant Pharmova Limited Approves Executive and Board Changes

Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before September 7, 2022

Now 20% undervalued after recent price drop

Investor sentiment improved over the past week

Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to ₹711

Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Second quarter 2022 earnings released: EPS ₹8.97 (vs ₹14.06 in 2Q 2021)